Risk assessment for thrombosis in cancer

Seminars in Thrombosis and Hemostasis

Volumn 40, Issue 3, 2014, Pages 319-324

  Gomes, Marcelo ^a   Khorana, Alok A ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

cancer; risk factors; risk score; venous thromboembolism

Indexed keywords

ANTIANEMIC AGENT; BEVACIZUMAB; D DIMER; HEMOGLOBIN; LENALIDOMIDE; PADGEM PROTEIN; SORAFENIB; SUNITINIB; TAMOXIFEN; THALIDOMIDE; THROMBOPLASTIN;

AGE; ARTICLE; BODY MASS; BRAIN CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; HEMOGLOBIN BLOOD LEVEL; HISTOLOGY; HUMAN; KIDNEY CANCER; LEUKOCYTE COUNT; LIVER CANCER; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; MYELOMA; PANCREAS CANCER; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; STOMACH CANCER; THROMBOCYTE COUNT; VARICOSIS; VENOUS THROMBOEMBOLISM; BLOOD; NEOPLASM; PATHOLOGY; THROMBOSIS;

HUMANS; NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS;

EID: 84897954632     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1370770     Document Type: Article

References (53)

1. Horsted F., West J., Grainge M. J. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med: 2012; 9 7 e1001275
2. Moore R. A., Adel N., Riedel E., et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol: 2011; 29 25 3466 3473
3. Maraveyas A., Waters J., Roy R., et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer: 2012; 48 9 1283 1292
4. Lyman G. H., Khorana A. A., Kuderer N. M., et al. American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol: 2013; 31 17 2189 2204
5. Khorana A. A., Francis C. W., Culakova E., Kuderer N. M., Lyman G. H. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer: 2007; 110 10 2339 2346
6. Samama M. M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med: 2000; 160 22 3415 3420
7. Königsbrügge O., Lötsch F., Reitter E. M., et al. Presence of varicose veins in cancer patients increases the risk for occurrence of venous thromboembolism. J Thromb Haemost: 2013; 11 11 1993 2000
8. Khorana A. A., Connolly G. C. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol: 2009; 27 29 4839 4847
9. Wun T., White R. H. Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma. Thromb Res: 2010; 125 02 S96 S102
10. Blom J. W., Doggen C. J., Osanto S., Rosendaal F. R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA: 2005; 293 6 715 722
11. Blom J. W., Osanto S., Rosendaal F. R. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost: 2004; 2 10 1760 1765
12. Chew H. K., Davies A. M., Wun T., Harvey D., Zhou H., White R. H. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost: 2008; 6 4 601 608
13. Ahlbrecht J., Dickmann B., Ay C., et al. Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol: 2012; 30 31 3870 3875
14. Dickmann B., Ahlbrecht J., Ay C., et al. Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica: 2013; 98 8 1309 1314
15. Marras L. C., Geerts W. H., Perry J. R. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer: 2000; 89 3 640 646
16. Lee A. Y., Levine M. N., Butler G., et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol: 2006; 24 9 1404 1408
17. Chopra V., Anand S., Hickner A., et al. Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis. Lancet: 2013; 382 9889 311 325
18. Elting L. S., Escalante C. P., Cooksley C., et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med: 2004; 164 15 1653 1661
19. Heit J. A., Silverstein M. D., Mohr D. N., Petterson T. M., O'Fallon W. M., Melton L. J. III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med: 2000; 160 6 809 815
20. Starling N., Rao S., Cunningham D., et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol: 2009; 27 23 3786 3793
21. Kabbinavar F., Hurwitz H. I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol: 2003; 21 1 60 65
22. Nalluri S. R., Chu D., Keresztes R., Zhu X., Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA: 2008; 300 19 2277 2285
23. Hurwitz H. I., Saltz L. B., Van Cutsem E., et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol: 2011; 29 13 1757 1764
24. Bennett C. L., Schumock G. T., Desai A. A., et al. Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am J Med: 2002; 113 7 603 606
25. Cavo M., Zamagni E., Cellini C., et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood: 2002; 100 6 2272 2273
26. Petrelli F., Borgonovo K., Cabiddu M., Ghilardi M., Barni S. Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf: 2012; 11 01 S9 S19
27. Trujillo-Santos J., Di Micco P., Iannuzzo M., et al. RIETE Investigators. Elevated white blood cell count and outcome in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost: 2008; 100 5 905 911
28. Trujillo-Santos J., Nieto J. A., Tiberio G., et al. RIETE Registry. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost: 2008; 100 3 435 439
29. Louzada M. L., Majeed H., Dao V., Wells P. S. Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies. Blood Coagul Fibrinolysis: 2011; 22 2 86 91
30. Hutten B. A., Prins M. H., Gent M., Ginsberg J., Tijssen J. G., Büller H. R. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol: 2000; 18 17 3078 3083
31. Louzada M. L., Carrier M., Lazo-Langner A., et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation: 2012; 126 4 448 454
32. Pabinger I., Thaler J., Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood: 2013; 122 12 2011 2018
33. Bharthuar A., Khorana A. A., Hutson A., et al. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res: 2013; 132 2 180 184
34. Thaler J., Ay C., Mackman N., et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost: 2012; 10 7 1363 1370
35. Agnelli G., Gussoni G., Bianchini C., et al. PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol: 2009; 10 10 943 949
36. Agnelli G., George D. J., Kakkar A. K., et al. SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med: 2012; 366 7 601 609
37. Khorana A. A., Kuderer N. M., Culakova E., Lyman G. H., Francis C. W. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood: 2008; 111 10 4902 4907
38. Ay C., Dunkler D., Marosi C., et al. Prediction of venous thromboembolism in cancer patients. Blood: 2010; 116 24 5377 5382
39. Khorana A. A. Cancer and coagulation. Am J Hematol: 2012; 87 01 S82 S87
40. Streiff M. B., Bockenstedt P. L., Cataland S. R., et al. Venous thromboembolic disease. J Natl Compr Canc Netw: 2013; 11 1402 1429
41. Mandalà M., Falanga A., Roila F.; ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol: 2011; 22 06 vi85 vi92
42. Palumbo A., Rajkumar S. V., Dimopoulos M. A., et al. International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia: 2008; 22 2 414 423
43. Sousou T., Khorana A. A. Cancer patients and awareness of venous thromboembolism. Cancer Invest: 2010; 28 1 44 45
44. Verso M., Agnelli G., Barni S., Gasparini G., LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med: 2012; 7 3 291 292
45. George D., Agnelli G., Fisher W., et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO. Blood (ASH Annual Meeting Program and Proceedings): 2011; 118: Abstract 206
46. Stender M. T., Frokjaer J. B., Larsen T. B., Lundbye-Christensen S., Thorlacius-Ussing O. Preoperative plasma D-dimer is a predictor of postoperative deep venous thrombosis in colorectal cancer patients: a clinical, prospective cohort study with one-year follow-up. Dis Colon Rectum: 2009; 52 3 446 451
47. Ay C., Vormittag R., Dunkler D., et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol: 2009; 27 25 4124 4129
48. Ay C., Dunkler D., Simanek R., et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol: 2011; 29 15 2099 2103
49. Khorana A. A., Ahrendt S. A., Ryan C. K., et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res: 2007; 13 10 2870 2875
50. Khorana A. A., Francis C. W., Menzies K. E., et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost: 2008; 6 11 1983 1985
51. Zwicker J. I., Liebman H. A., Neuberg D., et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res: 2009; 15 22 6830 6840
52. Ay C., Simanek R., Vormittag R., et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood: 2008; 112 7 2703 2708
53. Vormittag R., Simanek R., Ay C., et al. High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol: 2009; 29 12 2176 2181